Kristina Hagenström
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristina Hagenström has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Matthias Augustin
Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP) Universitätsklinikum Hamburg‐Eppendorf (UKE) Hamburg Deutschland
25 shared publications - Theresa Klinger
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
9 shared publications Claudia Garbe
Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP) Universitätsklinikum Hamburg‐Eppendorf (UKE), Hamburg, Deutschland
8 shared publicationsKatharina Müller
Competenzzentrum Versorgungsforschung in der Dermatologie (CVderm) Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP) Universitätsklinikum Hamburg‐Eppendorf (UKE), Hamburg
7 shared publicationsAlexander Katalinic
Institut für Sozialmedizin und Epidemiologie Universität zu Lübeck, Lübeck, Deutschland
5 shared publicationsJoachim Hübner
Institut für Sozialmedizin und Epidemiologie Universität zu Lübeck, Lübeck, Deutschland
5 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (10)
Underprovision of Medical Compression Therapy: Retrospective Analysis Based on Statutory Health Insurance Data on Venous Leg Ulcers, Chronic Venous Disease and Comorbidities
Chronic venous diseases (CVD), including venous leg ulcers (VLU), represent a significant health burden. Despite the central role of compression therapy in current treatment guidelines, recent evidence suggests substantial gaps in provision. A retrospective cohort study was conducted using anonymized claims data from 3.35 million insured individuals. Persons with VLU or CVD in 2017 were observed over 5 years. Compression therapy, comorbidities, antibiotic prescriptions, and physician contacts were analysed. The prevalence was 0.50% for VLU ( n = 16 615) and 7.27% for CVD ( n = 243 681). Across 5 years, 75.85% (VLU) and 53.10% (CVD) received compression therapy. However, 24.15% of persons with VLU were not treated with compression therapy. Persons receiving compression were predominantly female and older (VLU: 74.13 years, 59.56% women; CVD: 68.55 years, 70.86% women), exhibited a higher mean Charlson Comorbidity Index (CCI [95% CI]: VLU 4.09 [4.03–4.15], CVD 2.67 [2.65–2.68] vs. VLU 3.14 [3.05–3.23], CVD 2.12 [2.11–2.14] without compression). In the first year post‐diagnosis, 51.43% VLU persons with compression received antibacterials (vs. 36.28%). The data confirm prior estimates of disease prevalence and highlight a substantial gap in the documented use of guideline‐compliant compression therapy, especially in VLU. High multimorbidity and care intensity underscore the need for better integration of compression therapy in routine practice.
- 5 October 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (10)
Open AccessUnderprovision of Medical Compression Therapy: Retrospective Analysis Based on Statutory Health Insurance Data on Venous Leg Ulcers, Chronic Venous Disease and Comorbidities
Chronic venous diseases (CVD), including venous leg ulcers (VLU), represent a significant health burden. Despite the central role of compression therapy in current treatment guidelines, recent evidence suggests substantial gaps in provision. A retrospective cohort study was conducted using anonymized claims data from 3.35 million insured individuals. Persons with VLU or CVD in 2017 were observed over 5 years. Compression therapy, comorbidities, antibiotic prescriptions, and physician contacts were analysed. The prevalence was 0.50% for VLU ( n = 16 615) and 7.27% for CVD ( n = 243 681). Across 5 years, 75.85% (VLU) and 53.10% (CVD) received compression therapy. However, 24.15% of persons with VLU were not treated with compression therapy. Persons receiving compression were predominantly female and older (VLU: 74.13 years, 59.56% women; CVD: 68.55 years, 70.86% women), exhibited a higher mean Charlson Comorbidity Index (CCI [95% CI]: VLU 4.09 [4.03–4.15], CVD 2.67 [2.65–2.68] vs. VLU 3.14 [3.05–3.23], CVD 2.12 [2.11–2.14] without compression). In the first year post‐diagnosis, 51.43% VLU persons with compression received antibacterials (vs. 36.28%). The data confirm prior estimates of disease prevalence and highlight a substantial gap in the documented use of guideline‐compliant compression therapy, especially in VLU. High multimorbidity and care intensity underscore the need for better integration of compression therapy in routine practice.
- Open Access
- 7 July 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , 886-895
Epidemiologie des nummulären Ekzems – methodische Ansätze und Ergebnisse aus bundesweiten Routinedaten
Zusammenfassung: Hintergrund und Zielsetzung: Das nummuläre Ekzem (NE) ist eine chronische Hauterkrankung, für die nur wenige epidemiologische Daten vorliegen. Diese Studie schätzt die Prävalenz, Inzidenz und Schwere der Erkrankung in Deutschland. Methoden: In einer Querschnittsanalyse (2016–2022) wurden anhand von Daten der gesetzlichen Krankenversicherung Personen mit NE (ICD‐10 L30.0) identifiziert und der Schweregrad (Krankenhausaufenthalt, Arbeitsunfähigkeit, systemische Behandlung) sowie Begleiterkrankungen der Haut bewertet. Ergebnisse: Im Jahr 2022 lag die Prävalenz von NE zwischen 0,07% und 0,26%. Die Inzidenz betrug 0,16%–0,17%. Das Durchschnittsalter lag bei 47,5 Jahren, 57,4% der Patienten waren männlich. Ältere Männer wiesen eine höhere Prävalenz auf, während Kinder unter 6 Jahren (0,34%), insbesondere unter zwei Jahren (0,56%–0,57%), stärker betroffen waren. Schwere NE wurden bei 14,8% der Patienten festgestellt. Atopische Dermatitis trat bei 18% gleichzeitig auf. Personen mit NE hatten ein erhöhtes Risiko für Lichen simplex chronicus (RR 9,71), irritative Kontaktdermatitis (RR 9,60), Pruritus (RR 5,71), allergische Rhinitis (RR 1,78) und allergisches Asthma (RR 1,49). Schlussfolgerungen: Trotz unterschiedlicher methodischer Ansätze, die zu Abweichungen führten, kann die Prävalenz von NE mit etwa 0,26% angenommen werden. Überschneidungen und Fehlcodierungen sind mit anderen Formen von Ekzemen möglich, was die Notwendigkeit fundierter Diagnostik und standardisierter Kodierung nahelegt.
- 7 July 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , 886-895
Open AccessEpidemiologie des nummulären Ekzems – methodische Ansätze und Ergebnisse aus bundesweiten Routinedaten
Zusammenfassung: Hintergrund und Zielsetzung: Das nummuläre Ekzem (NE) ist eine chronische Hauterkrankung, für die nur wenige epidemiologische Daten vorliegen. Diese Studie schätzt die Prävalenz, Inzidenz und Schwere der Erkrankung in Deutschland. Methoden: In einer Querschnittsanalyse (2016–2022) wurden anhand von Daten der gesetzlichen Krankenversicherung Personen mit NE (ICD‐10 L30.0) identifiziert und der Schweregrad (Krankenhausaufenthalt, Arbeitsunfähigkeit, systemische Behandlung) sowie Begleiterkrankungen der Haut bewertet. Ergebnisse: Im Jahr 2022 lag die Prävalenz von NE zwischen 0,07% und 0,26%. Die Inzidenz betrug 0,16%–0,17%. Das Durchschnittsalter lag bei 47,5 Jahren, 57,4% der Patienten waren männlich. Ältere Männer wiesen eine höhere Prävalenz auf, während Kinder unter 6 Jahren (0,34%), insbesondere unter zwei Jahren (0,56%–0,57%), stärker betroffen waren. Schwere NE wurden bei 14,8% der Patienten festgestellt. Atopische Dermatitis trat bei 18% gleichzeitig auf. Personen mit NE hatten ein erhöhtes Risiko für Lichen simplex chronicus (RR 9,71), irritative Kontaktdermatitis (RR 9,60), Pruritus (RR 5,71), allergische Rhinitis (RR 1,78) und allergisches Asthma (RR 1,49). Schlussfolgerungen: Trotz unterschiedlicher methodischer Ansätze, die zu Abweichungen führten, kann die Prävalenz von NE mit etwa 0,26% angenommen werden. Überschneidungen und Fehlcodierungen sind mit anderen Formen von Ekzemen möglich, was die Notwendigkeit fundierter Diagnostik und standardisierter Kodierung nahelegt.
- Open Access
- 22 June 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (8) , 4067-4082
Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study
Systemic glucocorticosteroids (SGCs) are recommended only for short-term treatment of atopic dermatitis (AD) because of their side effect profile. Nevertheless, prolonged and repeated use remains common in routine care. Evidence on whether treatment duration or cumulative dose is the main driver of adverse events is limited. Therefore, the aim of this study is to investigate the longitudinal association between SGC treatment duration and side effects in persons with AD and to compare its impact with cumulative dose. This was a retrospective cohort study based on German statutory health insurance data that included persons with AD initiating SGC therapy. Associations between SGC exposure and side effect were analyzed using logistic regression and adjusted time-dependent Cox models. Longer treatment duration was associated with higher odds of multiple side effects, including osteoporosis (odds ratio [OR] 1.21-1.27). In time-dependent Cox models, each additional quarter of SGC therapy increased the hazard of mental disorders (hazard ratio [HR] 1.21; 95% confidence interval [CI] 1.10-1.32), gastritis/duodenitis (HR 1.07; 1.00-1.15), osteoporosis (HR 1.37; 1.23-1.52), hypertension (HR 1.26; 1.08-1.48), and diabetes mellitus (HR 1.35; 1.09-1.69). Prolonged SGC therapy is associated with increasing risks of multiple side effects, supporting guideline recommendations for short-term use only. Documented SGC treatment duration showed more consistent associations with side effects than cumulative dose.
- 22 June 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (8) , 4067-4082
Open AccessDuration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study
Systemic glucocorticosteroids (SGCs) are recommended only for short-term treatment of atopic dermatitis (AD) because of their side effect profile. Nevertheless, prolonged and repeated use remains common in routine care. Evidence on whether treatment duration or cumulative dose is the main driver of adverse events is limited. Therefore, the aim of this study is to investigate the longitudinal association between SGC treatment duration and side effects in persons with AD and to compare its impact with cumulative dose. This was a retrospective cohort study based on German statutory health insurance data that included persons with AD initiating SGC therapy. Associations between SGC exposure and side effect were analyzed using logistic regression and adjusted time-dependent Cox models. Longer treatment duration was associated with higher odds of multiple side effects, including osteoporosis (odds ratio [OR] 1.21-1.27). In time-dependent Cox models, each additional quarter of SGC therapy increased the hazard of mental disorders (hazard ratio [HR] 1.21; 95% confidence interval [CI] 1.10-1.32), gastritis/duodenitis (HR 1.07; 1.00-1.15), osteoporosis (HR 1.37; 1.23-1.52), hypertension (HR 1.26; 1.08-1.48), and diabetes mellitus (HR 1.35; 1.09-1.69). Prolonged SGC therapy is associated with increasing risks of multiple side effects, supporting guideline recommendations for short-term use only. Documented SGC treatment duration showed more consistent associations with side effects than cumulative dose.
- Open Access
- 29 April 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106, adv44468
Epidemiology and Comorbidity of Vitiligo in Germany: A Claims Data Analysis
Vitiligo is a chronic skin disease resulting in destruction of melanocytes and loss of pigmentation. Little is known about epidemiology and comorbidity in Germany. This retrospective cohort analysis used nationwide statutory health insurance data (2016 to 2020). Disease rates were calculated using varying case definitions. Comorbidity was assessed against 3 control groups: persons without vitiligo, with atopic dermatitis, and with psoriasis (1:3 propensity score matching). In 2020, 4,631 persons were diagnosed with vitiligo in DAK-Gesundheit (DAK-G, mean age 56.93 years, ~148,437) and 5,820 persons in the German Analysis Database for Evaluation and Health Services Research (~144,855). Prevalence ranged from 0.12% (confidence interval [CI] 0.12–0.12) to 0.20% (CI 0.19–0.20), and incidence from 0.04% (CI 0.03–0.04) to 0.06% (CI 0.06–0.06). Rates increased with age. Women (mean age 58.60 years) were more frequently affected. Vitiligo was associated with alopecia areata (relative risk 7.14, CI 4.63–11.00) and systemic sclerosis (relative risk 3.20, CI 1.58–6.47). Several mental illnesses (depression: relative risk = 1.23, CI 1.15–1.32, anxiety: relative risk = 1.32, CI 1.19–1.47), were linked to skin diseases like vitiligo, atopic dermatitis, or psoriasis. Vitiligo affects a notable proportion of the population, with detected comorbidities supporting prior findings. To ensure reliable results, claims data should be validated through primary data linkage or sensitivity testing.
- 29 April 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106, adv44468
Open AccessEpidemiology and Comorbidity of Vitiligo in Germany: A Claims Data Analysis
Vitiligo is a chronic skin disease resulting in destruction of melanocytes and loss of pigmentation. Little is known about epidemiology and comorbidity in Germany. This retrospective cohort analysis used nationwide statutory health insurance data (2016 to 2020). Disease rates were calculated using varying case definitions. Comorbidity was assessed against 3 control groups: persons without vitiligo, with atopic dermatitis, and with psoriasis (1:3 propensity score matching). In 2020, 4,631 persons were diagnosed with vitiligo in DAK-Gesundheit (DAK-G, mean age 56.93 years, ~148,437) and 5,820 persons in the German Analysis Database for Evaluation and Health Services Research (~144,855). Prevalence ranged from 0.12% (confidence interval [CI] 0.12–0.12) to 0.20% (CI 0.19–0.20), and incidence from 0.04% (CI 0.03–0.04) to 0.06% (CI 0.06–0.06). Rates increased with age. Women (mean age 58.60 years) were more frequently affected. Vitiligo was associated with alopecia areata (relative risk 7.14, CI 4.63–11.00) and systemic sclerosis (relative risk 3.20, CI 1.58–6.47). Several mental illnesses (depression: relative risk = 1.23, CI 1.15–1.32, anxiety: relative risk = 1.32, CI 1.19–1.47), were linked to skin diseases like vitiligo, atopic dermatitis, or psoriasis. Vitiligo affects a notable proportion of the population, with detected comorbidities supporting prior findings. To ensure reliable results, claims data should be validated through primary data linkage or sensitivity testing.
- Open Access
- 6 March 2026
- Published by Nofer Institute of Occupational Medicine in International Journal of Occupational Medicine and Environmental Health
- Vol. 39 (1) , 68-78
Prevalence and occupational risk of hip osteoarthritis and rotator cuff lesions – claims data analysis
Objectives: Hip osteoarthritis (OA) and rotator cuff lesions (RCL) are major musculoskeletal disorders that cause chronic pain, reduced mobility, and work incapacity. While certain occupational groups have been studied, limited data exist on other physically demanding professions typically...
- 6 March 2026
- Published by Nofer Institute of Occupational Medicine in International Journal of Occupational Medicine and Environmental Health
- Vol. 39 (1) , 68-78
Open AccessPrevalence and occupational risk of hip osteoarthritis and rotator cuff lesions – claims data analysis
Objectives: Hip osteoarthritis (OA) and rotator cuff lesions (RCL) are major musculoskeletal disorders that cause chronic pain, reduced mobility, and work incapacity. While certain occupational groups have been studied, limited data exist on other physically demanding professions typically...
- Open Access
Prevalence and comparative risk of mental health disorders in persons with vitiligo: a retrospective matched cohort study using claims data with expert-informed case validation
Objectives To estimate the prevalence and comorbidity patterns of mental health disorders (MHDs) in persons with vitiligo and compare relative risks (RRs) with dermatological diseases (atopic dermatitis and psoriasis) and non-vitiligo comparator cohorts using claims data. Design Retrospective matched cohort study using nationwide statutory health insurance claims data. Setting German statutory health insurance claims (DAK-Gesundheit), 2016–2020. Participants A 40% anonymised sample of insured persons (N=2 885 984). In 2020, persons with vitiligo (International Statistical Classification of Diseases, Tenth Revision, German Modification L80) were compared with cohorts with atopic dermatitis (L20), psoriasis (L40) and persons without vitiligo. Cohorts were propensity score matched (1:3) by age and sex. Primary outcome measures Prevalence of MHDs and RRs across comparator cohorts. Secondary outcome measures Internal plausibility of expert-informed claims-based MHD case definitions using diagnosis-only versus diagnosis-plus-care criteria. Results In 2020, 4 631 persons were diagnosed with vitiligo. Affective disorders and neurotic, stress-related and somatoform disorders showed the highest prevalence, with depressive episodes ranging from 8.9% to 19.2% and somatoform disorders from 5.3% to 17.9% across definitions. In matched comparisons with atopic dermatitis, only a few and inconsistent differences were observed. In contrast, more pronounced and consistent differences were identified in comparisons with psoriasis. Emotional disorders in childhood showed higher risks under the most sensitive case definition (RR=2.29, 95% CI 1.14 to 4.61), whereas hyperkinetic disorders showed consistent effects across all definitions (RR range=1.58–1.93). Compared with persons without vitiligo, risks were higher for social phobia (RR range=2.10–2.81) and anxiety disorders (RR range=1.64–1.93). Conclusions Persons with vitiligo show a substantial burden of affective and stress-related MHDs. The mental health comorbidity profile was largely comparable to that of atopic dermatitis, whereas more pronounced differences were observed in comparisons with psoriasis. Claims-based prevalence estimates were sensitive to case definition, highlighting the importance of transparent operationalisation.
Open AccessPrevalence and comparative risk of mental health disorders in persons with vitiligo: a retrospective matched cohort study using claims data with expert-informed case validation
Objectives To estimate the prevalence and comorbidity patterns of mental health disorders (MHDs) in persons with vitiligo and compare relative risks (RRs) with dermatological diseases (atopic dermatitis and psoriasis) and non-vitiligo comparator cohorts using claims data. Design Retrospective matched cohort study using nationwide statutory health insurance claims data. Setting German statutory health insurance claims (DAK-Gesundheit), 2016–2020. Participants A 40% anonymised sample of insured persons (N=2 885 984). In 2020, persons with vitiligo (International Statistical Classification of Diseases, Tenth Revision, German Modification L80) were compared with cohorts with atopic dermatitis (L20), psoriasis (L40) and persons without vitiligo. Cohorts were propensity score matched (1:3) by age and sex. Primary outcome measures Prevalence of MHDs and RRs across comparator cohorts. Secondary outcome measures Internal plausibility of expert-informed claims-based MHD case definitions using diagnosis-only versus diagnosis-plus-care criteria. Results In 2020, 4 631 persons were diagnosed with vitiligo. Affective disorders and neurotic, stress-related and somatoform disorders showed the highest prevalence, with depressive episodes ranging from 8.9% to 19.2% and somatoform disorders from 5.3% to 17.9% across definitions. In matched comparisons with atopic dermatitis, only a few and inconsistent differences were observed. In contrast, more pronounced and consistent differences were identified in comparisons with psoriasis. Emotional disorders in childhood showed higher risks under the most sensitive case definition (RR=2.29, 95% CI 1.14 to 4.61), whereas hyperkinetic disorders showed consistent effects across all definitions (RR range=1.58–1.93). Compared with persons without vitiligo, risks were higher for social phobia (RR range=2.10–2.81) and anxiety disorders (RR range=1.64–1.93). Conclusions Persons with vitiligo show a substantial burden of affective and stress-related MHDs. The mental health comorbidity profile was largely comparable to that of atopic dermatitis, whereas more pronounced differences were observed in comparisons with psoriasis. Claims-based prevalence estimates were sensitive to case definition, highlighting the importance of transparent operationalisation.
- Open Access
- 16 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , 886-893
Epidemiology of nummular eczema – methodological approaches and outcomes from nationwide claims data analyses
Summary: Background and Objectives: Nummular eczema (NE) is a chronic skin condition with limited epidemiologic data. This study estimates its prevalence, incidence and severity in Germany. Methods: A cross‐sectional analysis (2016–2022) used German insurance claims data to identify NE cases (ICD‐10 L30.0) and assess severity (hospitalization, work disability, systemic treatment) and comorbid skin conditions, including atopic dermatitis (AD). Results: In 2022, the prevalence of NE ranged from 0.07% to 0.26%. The incidence was 0.16%–0.17%. The mean age was 47.5 years, and 57.4% of the patients were male. Older males had a higher prevalence, while children younger than six years (0.34%), especially those younger than 2 years (0.56%–0.57%), were more affected. Severe NE was found in 14.8% of the patients. AD co‐occurred in 18% of NE cases. NE patients had an increased risk of lichen simplex chronicus (RR 9.71), irritant contact dermatitis (RR 9.60), pruritus (RR 5.71), allergic rhinitis (RR 1.78), and allergic asthma (RR 1.49). Conclusions: Despite differences in methodological approaches leading to some variation, the prevalence of NE in the German population can be reasonably estimated at approximately 0.26%. Overlaps and miscoding may have occurred, particularly with other forms of eczema, underscoring the need for reliable diagnostics and standardized coding.
- 16 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , 886-893
Open AccessEpidemiology of nummular eczema – methodological approaches and outcomes from nationwide claims data analyses
Summary: Background and Objectives: Nummular eczema (NE) is a chronic skin condition with limited epidemiologic data. This study estimates its prevalence, incidence and severity in Germany. Methods: A cross‐sectional analysis (2016–2022) used German insurance claims data to identify NE cases (ICD‐10 L30.0) and assess severity (hospitalization, work disability, systemic treatment) and comorbid skin conditions, including atopic dermatitis (AD). Results: In 2022, the prevalence of NE ranged from 0.07% to 0.26%. The incidence was 0.16%–0.17%. The mean age was 47.5 years, and 57.4% of the patients were male. Older males had a higher prevalence, while children younger than six years (0.34%), especially those younger than 2 years (0.56%–0.57%), were more affected. Severe NE was found in 14.8% of the patients. AD co‐occurred in 18% of NE cases. NE patients had an increased risk of lichen simplex chronicus (RR 9.71), irritant contact dermatitis (RR 9.60), pruritus (RR 5.71), allergic rhinitis (RR 1.78), and allergic asthma (RR 1.49). Conclusions: Despite differences in methodological approaches leading to some variation, the prevalence of NE in the German population can be reasonably estimated at approximately 0.26%. Overlaps and miscoding may have occurred, particularly with other forms of eczema, underscoring the need for reliable diagnostics and standardized coding.
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 15, 327-338
Utilization and Costs of Laboratory Monitoring in Biological and Non-Biological Psoriasis Treatment – Large-Scale Claims Data Analysis
Purpose: Psoriasis vulgaris is a chronic systemic inflammatory disease that imposes a significant physical, emotional, and social burden on affected individuals. There is a growing recognition of the importance of comprehensive monitoring and management to optimize treatment outcomes, particularly with the advent of advanced systemic therapies. This study aims to characterize the prevalence of laboratory monitoring and associated costs in persons with psoriasis undergoing systemic treatment. A specific focus was placed on the differences by treatment modality, patient characteristics, and economic burden to the payers. Patients and Methods: A retrospective longitudinal analysis was conducted using German health insurance data from the DAK-Gesundheit. The study population included persons diagnosed with psoriasis who received systemic therapies between 2016 and 2020. Laboratory service utilization and costs were assessed during the initiation and course of treatment, factoring in demographic parameters and comorbidities. Results: Among 62,063 persons with psoriasis, 8018 (12.9%) were identified as having received systemic treatment, which of 92.5% utilized at least one laboratory service. The average annual laboratory monitoring cost per person was higher for those on biologic therapies (57.88 €) compared to systemic treatments (23.70 €). Laboratory service utilization and costs were associated with the comorbidity index (CCI) and age. Conclusion: Biologic therapies for psoriasis induce considerably higher monitoring costs than non-biological systemic drugs. Age and CCI were main predictors for higher utilization of laboratory services, indicating a medical rationale to perform more lab screenings in risk groups for safety events. The laboratory costs add to the higher drug costs of biologicals but need to be related to the benefits from treatment. Furthermore, the monitoring costs are far lower than the drug costs and thus may not be major decision drivers.
- 1 August 2025
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 15, 327-338
Open AccessUtilization and Costs of Laboratory Monitoring in Biological and Non-Biological Psoriasis Treatment – Large-Scale Claims Data Analysis
Purpose: Psoriasis vulgaris is a chronic systemic inflammatory disease that imposes a significant physical, emotional, and social burden on affected individuals. There is a growing recognition of the importance of comprehensive monitoring and management to optimize treatment outcomes, particularly with the advent of advanced systemic therapies. This study aims to characterize the prevalence of laboratory monitoring and associated costs in persons with psoriasis undergoing systemic treatment. A specific focus was placed on the differences by treatment modality, patient characteristics, and economic burden to the payers. Patients and Methods: A retrospective longitudinal analysis was conducted using German health insurance data from the DAK-Gesundheit. The study population included persons diagnosed with psoriasis who received systemic therapies between 2016 and 2020. Laboratory service utilization and costs were assessed during the initiation and course of treatment, factoring in demographic parameters and comorbidities. Results: Among 62,063 persons with psoriasis, 8018 (12.9%) were identified as having received systemic treatment, which of 92.5% utilized at least one laboratory service. The average annual laboratory monitoring cost per person was higher for those on biologic therapies (57.88 €) compared to systemic treatments (23.70 €). Laboratory service utilization and costs were associated with the comorbidity index (CCI) and age. Conclusion: Biologic therapies for psoriasis induce considerably higher monitoring costs than non-biological systemic drugs. Age and CCI were main predictors for higher utilization of laboratory services, indicating a medical rationale to perform more lab screenings in risk groups for safety events. The laboratory costs add to the higher drug costs of biologicals but need to be related to the benefits from treatment. Furthermore, the monitoring costs are far lower than the drug costs and thus may not be major decision drivers.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 15, 273-283
Epidemiology and Health Care of Generalized Pustular Psoriasis in Germany – Methodology and Outcomes of Claims Data Analysis
Purpose: Epidemiological and health care data on generalized pustular psoriasis (GPP) show large differences in literature. This study assessed GPP epidemiology, comorbidities and health care in Germany. Patients and Methods: Nationwide population-related German claims data were analyzed using different case definitions for internal validation. Results: In 2019, the prevalence of GPP in Germany in adults ranged from 8 to 39 and incidence from 1 to 15 persons per 100,000. Prevalence was higher in women and increased with age. Thirty-three percent had at least one other psoriatic ICD-10 code. People with GPP had significantly more skin diseases as well as cardiovascular and mental diseases than persons without psoriasis/GPP. The average annual drug costs per capita were € 2050 and were highest in those receiving biologicals (€ 15,524). Marked differences in treatment by specialist were observed. Conclusion: Acknowledging that the observed frequency or costs associated with GPP may be underestimated due to a few inherent limitations is important. Differences in GPP coding behavior and diagnostic accuracy may contribute to variations in epidemiology. The high disease burden is reflected by high annual costs and by significant comorbidity. Plain Language Summary: Generalized pustular psoriasis (GPP) is a severe form of psoriasis that causes painful, pus-filled blisters on the skin. Our study, conducted in Germany, aimed to explore how common GPP is, what other health problems people with GPP experience, and how they are treated. We analyzed health insurance data from across the country, using various methods to ensure our findings were accurate. We found that GPP is a rare condition compared to other types of psoriasis, affecting between 8 and 39 adults per 100,000 people in Germany in 2019. The number of people with GPP varied, with new cases ranging from 1 to 15 per 100,000 people. GPP was more common in women and increased with age. In addition, about a third of people with GPP also had other types of psoriasis. People with GPP had more skin diseases, heart problems, and mental health problems than people without psoriasis. The average annual cost of treating GPP was € 2050 per person, but this amount could be as high as € 15,524 for those receiving advanced treatments known as biologics. We also saw significant differences in how GPP is treated depending on which specialist was involved. In conclusion, our study highlights that GPP is a costly condition with a high burden of additional health problems. Variations in how GPP is diagnosed and coded might explain differences in reported prevalence and costs. Improving diagnostic accuracy and treatment approaches could lead to better care and reduced expenses for patients.
- 1 July 2025
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 15, 273-283
Open AccessEpidemiology and Health Care of Generalized Pustular Psoriasis in Germany – Methodology and Outcomes of Claims Data Analysis
Purpose: Epidemiological and health care data on generalized pustular psoriasis (GPP) show large differences in literature. This study assessed GPP epidemiology, comorbidities and health care in Germany. Patients and Methods: Nationwide population-related German claims data were analyzed using different case definitions for internal validation. Results: In 2019, the prevalence of GPP in Germany in adults ranged from 8 to 39 and incidence from 1 to 15 persons per 100,000. Prevalence was higher in women and increased with age. Thirty-three percent had at least one other psoriatic ICD-10 code. People with GPP had significantly more skin diseases as well as cardiovascular and mental diseases than persons without psoriasis/GPP. The average annual drug costs per capita were € 2050 and were highest in those receiving biologicals (€ 15,524). Marked differences in treatment by specialist were observed. Conclusion: Acknowledging that the observed frequency or costs associated with GPP may be underestimated due to a few inherent limitations is important. Differences in GPP coding behavior and diagnostic accuracy may contribute to variations in epidemiology. The high disease burden is reflected by high annual costs and by significant comorbidity. Plain Language Summary: Generalized pustular psoriasis (GPP) is a severe form of psoriasis that causes painful, pus-filled blisters on the skin. Our study, conducted in Germany, aimed to explore how common GPP is, what other health problems people with GPP experience, and how they are treated. We analyzed health insurance data from across the country, using various methods to ensure our findings were accurate. We found that GPP is a rare condition compared to other types of psoriasis, affecting between 8 and 39 adults per 100,000 people in Germany in 2019. The number of people with GPP varied, with new cases ranging from 1 to 15 per 100,000 people. GPP was more common in women and increased with age. In addition, about a third of people with GPP also had other types of psoriasis. People with GPP had more skin diseases, heart problems, and mental health problems than people without psoriasis. The average annual cost of treating GPP was € 2050 per person, but this amount could be as high as € 15,524 for those receiving advanced treatments known as biologics. We also saw significant differences in how GPP is treated depending on which specialist was involved. In conclusion, our study highlights that GPP is a costly condition with a high burden of additional health problems. Variations in how GPP is diagnosed and coded might explain differences in reported prevalence and costs. Improving diagnostic accuracy and treatment approaches could lead to better care and reduced expenses for patients.